GPAT: meta-analysis of COVID-19 studies

All studies   Hospitalization   Serious outcomes   Recovery   RCTs   Peer-reviewed   All outcomes  
Meta-analysis1 study · 243 patientsc19early.org

GPAT for COVID-19

Serious outcome risk
GPAT
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−38%
Hospitalization (1)−38%
RCTs (1)−38%
Early (1)−38%
00.511.5+
← GPAT
reduces riskIncreased
risk →
c19early.org
October 2026

GPAT COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
An (RCT)−38%1.38 · 1.05–1.81hosp.128 (n)115 (n)
Early treatment−38%1.38 · 1.05–1.81128 (n)115 (n)38% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.019
All studies−38%1.38 · 1.05–1.81128 (n)115 (n)38% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.01900.511.52+
Rotate screen for more detailsIncrease width for more details
← GPAT
reduces riskGPAT
increases risk →
c19early.org
October 2026

GPAT COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
An (RCT)−38%1.38 · 1.05–1.81hosp.128 (n)115 (n)
Early treatment−38%1.38 · 1.05–1.81128 (n)115 (n)38% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.019
All studies−38%1.38 · 1.05–1.81128 (n)115 (n)38% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.01900.511.52+
Rotate screen for more detailsIncrease width for more details
← GPAT
reduces riskGPAT
increases risk →
c19early.org
October 2026

GPAT COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
An (RCT)−38%1.38 · 1.05–1.81hosp.128 (n)115 (n)
Early treatment−38%1.38 · 1.05–1.81128 (n)115 (n)38% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.019
All studies−38%1.38 · 1.05–1.81128 (n)115 (n)38% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.01900.511.52+
Rotate screen for more detailsIncrease width for more details
← GPAT
reduces riskGPAT
increases risk →
c19early.org
October 2026

GPAT COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
An (RCT)−35%1.35 · 1.03–1.77no recov.128 (n)115 (n)
Early treatment−35%1.35 · 1.03–1.77128 (n)115 (n)35% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.028
All studies−35%1.35 · 1.03–1.77128 (n)115 (n)35% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.02800.511.52+
Rotate screen for more detailsIncrease width for more details
← GPAT
reduces riskGPAT
increases risk →
c19early.org
October 2026

GPAT COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
An (RCT)−38%1.38 · 1.05–1.81hosp.128 (n)115 (n)
Early treatment−38%1.38 · 1.05–1.81128 (n)115 (n)38% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.019
All studies−38%1.38 · 1.05–1.81128 (n)115 (n)38% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.01900.511.52+
Rotate screen for more detailsIncrease width for more details
← GPAT
reduces riskGPAT
increases risk →
c19early.org
October 2026

GPAT COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
An (RCT)−38%1.38 · 1.05–1.81hosp.128 (n)115 (n)
Early treatment−38%1.38 · 1.05–1.81128 (n)115 (n)38% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.019
All studies−38%1.38 · 1.05–1.81128 (n)115 (n)38% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.01900.511.52+
Rotate screen for more detailsIncrease width for more details
← GPAT
reduces riskGPAT
increases risk →